| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tablets | 115 | 2026 | 136 | 30.650 |
Why?
|
| Excipients | 61 | 2026 | 65 | 19.030 |
Why?
|
| Drug Compounding | 78 | 2026 | 99 | 18.810 |
Why?
|
| Powders | 82 | 2026 | 88 | 15.420 |
Why?
|
| Chemistry, Pharmaceutical | 59 | 2026 | 76 | 12.130 |
Why?
|
| Technology, Pharmaceutical | 31 | 2026 | 40 | 8.160 |
Why?
|
| Cellulose | 35 | 2025 | 61 | 8.110 |
Why?
|
| Solubility | 46 | 2025 | 187 | 7.440 |
Why?
|
| Crystallization | 55 | 2026 | 219 | 7.230 |
Why?
|
| Tensile Strength | 45 | 2026 | 88 | 6.200 |
Why?
|
| Particle Size | 46 | 2026 | 129 | 5.370 |
Why?
|
| Pressure | 27 | 2026 | 173 | 4.770 |
Why?
|
| Stearic Acids | 11 | 2025 | 12 | 3.770 |
Why?
|
| Pharmaceutical Preparations | 14 | 2025 | 109 | 3.730 |
Why?
|
| Carbamazepine | 6 | 2026 | 12 | 3.390 |
Why?
|
| Lactose | 13 | 2019 | 26 | 3.180 |
Why?
|
| Porosity | 29 | 2026 | 66 | 2.980 |
Why?
|
| Hardness | 18 | 2025 | 21 | 2.910 |
Why?
|
| Surface-Active Agents | 6 | 2024 | 58 | 2.890 |
Why?
|
| Acetaminophen | 6 | 2025 | 63 | 2.870 |
Why?
|
| Water | 18 | 2025 | 310 | 2.840 |
Why?
|
| Berberine | 4 | 2023 | 9 | 2.730 |
Why?
|
| Ibuprofen | 8 | 2025 | 35 | 2.610 |
Why?
|
| Thiazines | 6 | 2025 | 6 | 2.400 |
Why?
|
| Silicon Dioxide | 8 | 2022 | 40 | 2.150 |
Why?
|
| Biological Availability | 7 | 2025 | 86 | 2.110 |
Why?
|
| Sodium Dodecyl Sulfate | 5 | 2021 | 24 | 2.100 |
Why?
|
| Drug Liberation | 12 | 2024 | 19 | 1.980 |
Why?
|
| Lubricants | 4 | 2020 | 8 | 1.880 |
Why?
|
| Taste | 3 | 2020 | 29 | 1.770 |
Why?
|
| Solvents | 5 | 2025 | 91 | 1.720 |
Why?
|
| Surface Properties | 16 | 2026 | 129 | 1.690 |
Why?
|
| Drug Stability | 17 | 2025 | 48 | 1.640 |
Why?
|
| Pyrazines | 3 | 2024 | 98 | 1.550 |
Why?
|
| X-Ray Diffraction | 17 | 2025 | 131 | 1.530 |
Why?
|
| Duodenum | 2 | 2024 | 112 | 1.490 |
Why?
|
| Drug Industry | 4 | 2025 | 57 | 1.440 |
Why?
|
| Celecoxib | 7 | 2023 | 34 | 1.440 |
Why?
|
| Pyrrolidines | 4 | 2024 | 61 | 1.400 |
Why?
|
| Mannitol | 4 | 2019 | 49 | 1.390 |
Why?
|
| Drug Delivery Systems | 6 | 2025 | 200 | 1.320 |
Why?
|
| Povidone | 6 | 2024 | 8 | 1.300 |
Why?
|
| Flucytosine | 3 | 2016 | 11 | 1.290 |
Why?
|
| Administration, Oral | 12 | 2026 | 674 | 1.260 |
Why?
|
| Glass | 2 | 2025 | 17 | 1.250 |
Why?
|
| Models, Theoretical | 5 | 2025 | 508 | 1.230 |
Why?
|
| Piroxicam | 2 | 2020 | 11 | 1.200 |
Why?
|
| Coumaric Acids | 2 | 2019 | 6 | 1.190 |
Why?
|
| Antifungal Agents | 5 | 2024 | 126 | 1.190 |
Why?
|
| Glutarates | 2 | 2020 | 9 | 1.180 |
Why?
|
| Ritonavir | 2 | 2019 | 13 | 1.180 |
Why?
|
| Polymers | 7 | 2024 | 225 | 1.180 |
Why?
|
| Drug Carriers | 3 | 2020 | 90 | 1.170 |
Why?
|
| Models, Chemical | 8 | 2018 | 185 | 1.110 |
Why?
|
| Diphenhydramine | 2 | 2018 | 14 | 1.090 |
Why?
|
| Theophylline | 5 | 2024 | 34 | 1.050 |
Why?
|
| Salts | 3 | 2025 | 18 | 1.030 |
Why?
|
| X-Ray Microtomography | 2 | 2024 | 107 | 1.020 |
Why?
|
| Triazoles | 2 | 2024 | 118 | 1.010 |
Why?
|
| Oxalic Acid | 2 | 2019 | 8 | 1.000 |
Why?
|
| Glucuronosyltransferase | 4 | 2014 | 178 | 1.000 |
Why?
|
| Elastic Modulus | 5 | 2026 | 36 | 0.980 |
Why?
|
| Calcium Phosphates | 3 | 2017 | 85 | 0.980 |
Why?
|
| Citric Acid | 3 | 2018 | 47 | 0.980 |
Why?
|
| Physical Phenomena | 2 | 2023 | 7 | 0.970 |
Why?
|
| 4-Aminobenzoic Acid | 3 | 2024 | 6 | 0.970 |
Why?
|
| Nanoparticles | 6 | 2019 | 218 | 0.920 |
Why?
|
| Helium | 2 | 2023 | 13 | 0.920 |
Why?
|
| Levofloxacin | 1 | 2025 | 9 | 0.880 |
Why?
|
| Wettability | 8 | 2024 | 8 | 0.880 |
Why?
|
| Trimetazidine | 1 | 2025 | 4 | 0.880 |
Why?
|
| Vinyl Compounds | 4 | 2024 | 8 | 0.870 |
Why?
|
| Calorimetry, Differential Scanning | 8 | 2024 | 14 | 0.870 |
Why?
|
| Oxalates | 1 | 2025 | 49 | 0.860 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2016 | 53 | 0.810 |
Why?
|
| Humidity | 9 | 2023 | 96 | 0.810 |
Why?
|
| Stress, Mechanical | 4 | 2019 | 251 | 0.800 |
Why?
|
| Emulsions | 2 | 2020 | 20 | 0.790 |
Why?
|
| Aspirin | 2 | 2022 | 169 | 0.750 |
Why?
|
| Kinetics | 9 | 2024 | 1476 | 0.740 |
Why?
|
| Emollients | 1 | 2022 | 3 | 0.730 |
Why?
|
| Gastric Juice | 1 | 2022 | 15 | 0.730 |
Why?
|
| Compressive Strength | 8 | 2017 | 23 | 0.700 |
Why?
|
| Dicarboxylic Acids | 1 | 2021 | 24 | 0.670 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2025 | 255 | 0.650 |
Why?
|
| Allelic Imbalance | 2 | 2011 | 22 | 0.650 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2020 | 15 | 0.640 |
Why?
|
| Loratadine | 1 | 2020 | 21 | 0.640 |
Why?
|
| Temperature | 10 | 2024 | 442 | 0.640 |
Why?
|
| Parabens | 3 | 2019 | 3 | 0.630 |
Why?
|
| Diffusion | 4 | 2021 | 95 | 0.630 |
Why?
|
| Norfloxacin | 1 | 2019 | 3 | 0.620 |
Why?
|
| Sweetening Agents | 1 | 2020 | 17 | 0.620 |
Why?
|
| Poloxamer | 1 | 2019 | 24 | 0.620 |
Why?
|
| Quality Control | 5 | 2026 | 130 | 0.600 |
Why?
|
| Microscopy, Electron, Scanning | 7 | 2021 | 128 | 0.580 |
Why?
|
| Ionic Liquids | 1 | 2018 | 1 | 0.570 |
Why?
|
| Research Design | 1 | 2022 | 660 | 0.560 |
Why?
|
| Naproxen | 1 | 2018 | 14 | 0.560 |
Why?
|
| Fumarates | 1 | 2018 | 20 | 0.540 |
Why?
|
| Adhesiveness | 3 | 2026 | 5 | 0.540 |
Why?
|
| Rheology | 6 | 2024 | 38 | 0.540 |
Why?
|
| Niacinamide | 3 | 2021 | 105 | 0.540 |
Why?
|
| Chemical Engineering | 1 | 2017 | 2 | 0.530 |
Why?
|
| Histamine H1 Antagonists | 1 | 2017 | 39 | 0.520 |
Why?
|
| Hardness Tests | 2 | 2015 | 2 | 0.520 |
Why?
|
| Powder Diffraction | 4 | 2023 | 4 | 0.490 |
Why?
|
| Hydrochloric Acid | 2 | 2016 | 10 | 0.490 |
Why?
|
| Metformin | 1 | 2017 | 132 | 0.470 |
Why?
|
| Algorithms | 3 | 2017 | 2009 | 0.460 |
Why?
|
| Succinic Acid | 1 | 2015 | 11 | 0.460 |
Why?
|
| Thermodynamics | 5 | 2024 | 327 | 0.460 |
Why?
|
| Elasticity | 3 | 2025 | 98 | 0.460 |
Why?
|
| Biological Products | 3 | 2025 | 189 | 0.450 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2022 | 488 | 0.440 |
Why?
|
| Felodipine | 1 | 2014 | 1 | 0.440 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 2558 | 0.430 |
Why?
|
| Dipyridamole | 2 | 2024 | 12 | 0.410 |
Why?
|
| Chemical Precipitation | 4 | 2020 | 19 | 0.410 |
Why?
|
| Phase Transition | 4 | 2020 | 18 | 0.390 |
Why?
|
| Photoelectron Spectroscopy | 2 | 2026 | 3 | 0.390 |
Why?
|
| Linkage Disequilibrium | 2 | 2011 | 483 | 0.380 |
Why?
|
| Molecular Structure | 5 | 2020 | 305 | 0.370 |
Why?
|
| Stomach | 2 | 2024 | 110 | 0.370 |
Why?
|
| Flurbiprofen | 1 | 2012 | 1 | 0.360 |
Why?
|
| Vitamin B Complex | 1 | 2012 | 22 | 0.350 |
Why?
|
| Models, Molecular | 6 | 2022 | 1391 | 0.350 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2024 | 271 | 0.350 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2010 | 312 | 0.350 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2011 | 48 | 0.330 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 3 | 2019 | 105 | 0.330 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2011 | 298 | 0.330 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 102 | 0.330 |
Why?
|
| Crystallography, X-Ray | 3 | 2025 | 530 | 0.330 |
Why?
|
| Analgesics | 1 | 2012 | 131 | 0.330 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2024 | 42 | 0.320 |
Why?
|
| Climate | 1 | 2010 | 63 | 0.320 |
Why?
|
| Hypromellose Derivatives | 2 | 2020 | 4 | 0.310 |
Why?
|
| Materials Testing | 2 | 2019 | 96 | 0.310 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2024 | 1255 | 0.300 |
Why?
|
| Transition Temperature | 4 | 2016 | 10 | 0.290 |
Why?
|
| Sildenafil Citrate | 2 | 2020 | 24 | 0.280 |
Why?
|
| Liver | 2 | 2011 | 1231 | 0.280 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 204 | 0.270 |
Why?
|
| Methylcellulose | 2 | 2019 | 6 | 0.270 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 349 | 0.260 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 2787 | 0.260 |
Why?
|
| Permeability | 3 | 2025 | 145 | 0.260 |
Why?
|
| Alternative Splicing | 1 | 2009 | 224 | 0.260 |
Why?
|
| Organic Chemicals | 1 | 2007 | 38 | 0.260 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 2023 | 0.250 |
Why?
|
| Aspartame | 1 | 2006 | 6 | 0.250 |
Why?
|
| Steel | 1 | 2026 | 2 | 0.240 |
Why?
|
| Viscosity | 3 | 2025 | 52 | 0.240 |
Why?
|
| Drug Contamination | 1 | 2026 | 16 | 0.240 |
Why?
|
| Starch | 1 | 2025 | 9 | 0.240 |
Why?
|
| Ultrasonics | 1 | 2026 | 38 | 0.240 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2025 | 10 | 0.240 |
Why?
|
| Acoustics | 1 | 2026 | 48 | 0.240 |
Why?
|
| Desiccation | 2 | 2019 | 7 | 0.230 |
Why?
|
| Rats | 2 | 2024 | 4072 | 0.230 |
Why?
|
| Oryza | 1 | 2025 | 49 | 0.220 |
Why?
|
| Anisotropy | 1 | 2025 | 61 | 0.220 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 3272 | 0.220 |
Why?
|
| Diclofenac | 1 | 2025 | 4 | 0.220 |
Why?
|
| Picolinic Acids | 1 | 2025 | 8 | 0.220 |
Why?
|
| Pyrazoles | 1 | 2006 | 160 | 0.220 |
Why?
|
| Curcumin | 2 | 2015 | 19 | 0.220 |
Why?
|
| Amides | 1 | 2025 | 54 | 0.220 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2015 | 72 | 0.210 |
Why?
|
| Pharmacopoeias as Topic | 1 | 2024 | 1 | 0.210 |
Why?
|
| Humans | 24 | 2025 | 98135 | 0.210 |
Why?
|
| Crystallography | 3 | 2021 | 46 | 0.210 |
Why?
|
| Acetazolamide | 1 | 2024 | 10 | 0.210 |
Why?
|
| Animals | 7 | 2024 | 28902 | 0.200 |
Why?
|
| Lubrication | 1 | 2023 | 2 | 0.200 |
Why?
|
| Gastric Mucosa | 1 | 2024 | 72 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2014 | 1090 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2006 | 351 | 0.200 |
Why?
|
| Proteins | 1 | 2009 | 804 | 0.200 |
Why?
|
| Genotype | 4 | 2014 | 1888 | 0.190 |
Why?
|
| Pharmaceutical Research | 1 | 2022 | 3 | 0.190 |
Why?
|
| Genetic Variation | 1 | 2010 | 1445 | 0.190 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2023 | 325 | 0.190 |
Why?
|
| Chlorides | 1 | 2023 | 102 | 0.190 |
Why?
|
| Commerce | 1 | 2022 | 29 | 0.190 |
Why?
|
| Hydrogen Bonding | 2 | 2021 | 160 | 0.180 |
Why?
|
| Carboxylic Acids | 1 | 2022 | 16 | 0.180 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2022 | 86 | 0.180 |
Why?
|
| Dry Powder Inhalers | 1 | 2021 | 3 | 0.180 |
Why?
|
| Mentors | 1 | 2022 | 103 | 0.170 |
Why?
|
| Chitosan | 2 | 2019 | 17 | 0.170 |
Why?
|
| Equipment Design | 3 | 2019 | 427 | 0.170 |
Why?
|
| Micelles | 2 | 2018 | 56 | 0.170 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 425 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 67 | 0.160 |
Why?
|
| Gene Frequency | 3 | 2014 | 715 | 0.160 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 3 | 2021 | 29 | 0.160 |
Why?
|
| Dogs | 1 | 2021 | 639 | 0.160 |
Why?
|
| Flavoring Agents | 1 | 2020 | 11 | 0.160 |
Why?
|
| Binding Sites | 3 | 2019 | 1159 | 0.160 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 170 | 0.160 |
Why?
|
| Regulatory-Associated Protein of mTOR | 2 | 2010 | 12 | 0.160 |
Why?
|
| Saccharin | 1 | 2020 | 9 | 0.160 |
Why?
|
| Albendazole | 1 | 2019 | 3 | 0.160 |
Why?
|
| Nitrobenzoates | 1 | 2019 | 3 | 0.160 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2010 | 139 | 0.150 |
Why?
|
| Least-Squares Analysis | 2 | 2017 | 50 | 0.150 |
Why?
|
| Talc | 1 | 2019 | 4 | 0.150 |
Why?
|
| Muramidase | 1 | 2019 | 32 | 0.150 |
Why?
|
| Indomethacin | 1 | 2019 | 58 | 0.140 |
Why?
|
| Serum Albumin, Bovine | 1 | 2019 | 47 | 0.140 |
Why?
|
| Sodium Chloride | 1 | 2019 | 93 | 0.140 |
Why?
|
| Dosage Forms | 2 | 2026 | 8 | 0.140 |
Why?
|
| Caffeine | 1 | 2019 | 87 | 0.140 |
Why?
|
| Drug Storage | 1 | 2018 | 5 | 0.140 |
Why?
|
| Printing, Three-Dimensional | 1 | 2019 | 53 | 0.140 |
Why?
|
| Breast | 2 | 2011 | 315 | 0.140 |
Why?
|
| Prevalence | 1 | 2021 | 1383 | 0.130 |
Why?
|
| Glucosides | 1 | 2017 | 16 | 0.130 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 47 | 0.120 |
Why?
|
| Adsorption | 1 | 2016 | 52 | 0.120 |
Why?
|
| Polyethylene Glycols | 2 | 2015 | 382 | 0.120 |
Why?
|
| Stilbenes | 1 | 2016 | 26 | 0.120 |
Why?
|
| Specific Gravity | 2 | 2005 | 4 | 0.120 |
Why?
|
| Sulfamerazine | 2 | 2005 | 2 | 0.120 |
Why?
|
| Polyvinyls | 1 | 2015 | 23 | 0.120 |
Why?
|
| Salvia miltiorrhiza | 1 | 2015 | 3 | 0.120 |
Why?
|
| Amlodipine | 1 | 2015 | 5 | 0.110 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1783 | 0.110 |
Why?
|
| Cell Line | 2 | 2011 | 2482 | 0.110 |
Why?
|
| Glyburide | 1 | 2015 | 33 | 0.110 |
Why?
|
| Pharmaceutic Aids | 1 | 2015 | 2 | 0.110 |
Why?
|
| Time Factors | 4 | 2019 | 5576 | 0.110 |
Why?
|
| Injections, Subcutaneous | 2 | 2025 | 141 | 0.110 |
Why?
|
| Friction | 1 | 2015 | 5 | 0.110 |
Why?
|
| Nanocapsules | 1 | 2015 | 12 | 0.110 |
Why?
|
| Nanotechnology | 1 | 2015 | 74 | 0.110 |
Why?
|
| Rabbits | 1 | 2015 | 581 | 0.110 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 194 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 412 | 0.100 |
Why?
|
| Hot Temperature | 1 | 2014 | 228 | 0.100 |
Why?
|
| Thermogravimetry | 1 | 2013 | 1 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2015 | 422 | 0.100 |
Why?
|
| Male | 4 | 2024 | 47109 | 0.100 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2012 | 22 | 0.090 |
Why?
|
| Molecular Conformation | 1 | 2012 | 112 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2013 | 580 | 0.090 |
Why?
|
| Female | 6 | 2020 | 51570 | 0.090 |
Why?
|
| HapMap Project | 1 | 2011 | 47 | 0.090 |
Why?
|
| Protein Engineering | 1 | 2012 | 159 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2015 | 601 | 0.080 |
Why?
|
| Alleles | 2 | 2014 | 1159 | 0.080 |
Why?
|
| Manufactured Materials | 1 | 2010 | 2 | 0.080 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2010 | 20 | 0.080 |
Why?
|
| Retinoids | 1 | 2010 | 18 | 0.080 |
Why?
|
| Retinoid X Receptors | 1 | 2010 | 38 | 0.080 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2010 | 16 | 0.080 |
Why?
|
| Benzoates | 1 | 2010 | 33 | 0.080 |
Why?
|
| Hep G2 Cells | 1 | 2010 | 61 | 0.080 |
Why?
|
| Transcription Initiation Site | 1 | 2010 | 49 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2015 | 1153 | 0.080 |
Why?
|
| Mammography | 1 | 2014 | 504 | 0.080 |
Why?
|
| Geography | 1 | 2010 | 249 | 0.080 |
Why?
|
| Malonates | 1 | 2009 | 11 | 0.070 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2010 | 53 | 0.070 |
Why?
|
| Urea | 1 | 2009 | 54 | 0.070 |
Why?
|
| Dinucleotide Repeats | 1 | 2009 | 14 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2011 | 726 | 0.070 |
Why?
|
| Haplotypes | 1 | 2011 | 656 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2010 | 529 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2010 | 287 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 238 | 0.070 |
Why?
|
| Drug Design | 1 | 2009 | 135 | 0.070 |
Why?
|
| Introns | 1 | 2009 | 301 | 0.070 |
Why?
|
| Research | 1 | 2009 | 257 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 911 | 0.070 |
Why?
|
| Scattering, Radiation | 2 | 2019 | 122 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2010 | 449 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 3022 | 0.060 |
Why?
|
| Gene Expression | 1 | 2011 | 1320 | 0.060 |
Why?
|
| Young Adult | 1 | 2020 | 7511 | 0.060 |
Why?
|
| Protein Binding | 1 | 2010 | 1554 | 0.060 |
Why?
|
| Selection, Genetic | 1 | 2011 | 571 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1996 | 0.060 |
Why?
|
| Stereoisomerism | 1 | 2006 | 102 | 0.060 |
Why?
|
| Skin Absorption | 1 | 2025 | 5 | 0.060 |
Why?
|
| Light | 2 | 2019 | 290 | 0.060 |
Why?
|
| Mathematics | 1 | 2005 | 178 | 0.060 |
Why?
|
| Base Sequence | 1 | 2009 | 2222 | 0.060 |
Why?
|
| Spectrum Analysis, Raman | 2 | 2021 | 26 | 0.060 |
Why?
|
| Therapeutic Equivalency | 1 | 2024 | 16 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 87 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 2896 | 0.050 |
Why?
|
| Nifedipine | 1 | 2024 | 24 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2888 | 0.050 |
Why?
|
| Chemistry, Physical | 1 | 2004 | 29 | 0.050 |
Why?
|
| Chemical Phenomena | 1 | 2004 | 65 | 0.050 |
Why?
|
| Genome, Human | 1 | 2009 | 832 | 0.050 |
Why?
|
| Caco-2 Cells | 1 | 2023 | 128 | 0.050 |
Why?
|
| Intestinal Absorption | 1 | 2023 | 125 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2024 | 153 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2023 | 35 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 1566 | 0.050 |
Why?
|
| Linear Models | 1 | 2004 | 424 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2009 | 2063 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 1784 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2555 | 0.040 |
Why?
|
| Aerosols | 1 | 2021 | 44 | 0.040 |
Why?
|
| Chromatography, Gel | 1 | 2021 | 96 | 0.040 |
Why?
|
| Circular Dichroism | 1 | 2021 | 118 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2022 | 323 | 0.040 |
Why?
|
| Phospholipids | 1 | 2021 | 109 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 206 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2021 | 25 | 0.040 |
Why?
|
| Pyrans | 1 | 2020 | 10 | 0.040 |
Why?
|
| Freezing | 1 | 2020 | 30 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2015 | 137 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 2638 | 0.040 |
Why?
|
| Risk Factors | 1 | 2011 | 6232 | 0.040 |
Why?
|
| Materials Science | 1 | 2019 | 1 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2019 | 59 | 0.040 |
Why?
|
| Adult | 1 | 2020 | 29564 | 0.040 |
Why?
|
| Protein Unfolding | 1 | 2019 | 12 | 0.040 |
Why?
|
| Enzyme Stability | 1 | 2019 | 48 | 0.040 |
Why?
|
| Gelatin | 1 | 2019 | 27 | 0.040 |
Why?
|
| Protein Aggregates | 1 | 2019 | 28 | 0.040 |
Why?
|
| Static Electricity | 1 | 2019 | 101 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 85 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 65 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 239 | 0.030 |
Why?
|
| Cattle | 1 | 2019 | 397 | 0.030 |
Why?
|
| Proteolysis | 1 | 2019 | 129 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2019 | 340 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2019 | 731 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 126 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 643 | 0.030 |
Why?
|
| para-Aminobenzoates | 1 | 2016 | 7 | 0.030 |
Why?
|
| Models, Biological | 1 | 2023 | 1809 | 0.030 |
Why?
|
| Freeze Drying | 1 | 2015 | 17 | 0.030 |
Why?
|
| Biopharmaceutics | 1 | 2015 | 1 | 0.030 |
Why?
|
| Benzamides | 1 | 2016 | 260 | 0.030 |
Why?
|
| Camptothecin | 1 | 2015 | 198 | 0.030 |
Why?
|
| Fourier Analysis | 1 | 2014 | 124 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 308 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 945 | 0.020 |
Why?
|
| Multigene Family | 1 | 2014 | 204 | 0.020 |
Why?
|
| Neutrons | 1 | 2012 | 57 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 310 | 0.020 |
Why?
|
| Capsules | 1 | 2010 | 39 | 0.020 |
Why?
|
| Middle Aged | 1 | 2011 | 29442 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 977 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 153 | 0.020 |
Why?
|
| Software | 1 | 2014 | 695 | 0.020 |
Why?
|
| Choline | 1 | 2009 | 23 | 0.020 |
Why?
|
| Microscopy | 1 | 2009 | 92 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2005 | 53 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 831 | 0.010 |
Why?
|